Droxidopa in Treating Patients With Neurogenic Hypotension - Full Text View

Purpose

Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880.

RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal. It causes one to feel dizzy, light headed, and weak. Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure. Droxidopa, a drug that may increase blood pressure, may be an effective treatment for neurogenic hypotension.

PURPOSE: Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension.

Condition	Intervention
Shy-Drager Syndrome Orthostatic Hypotension	Drug: droxidopa

Genetics Home Reference related topics:

familial paroxysmal nonkinesigenic dyskinesia

MedlinePlus related topics:

Low Blood Pressure

Drug Information available for:

Droxidopa

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Study of Droxidopa in Patients With Neurologic Hypotension

Further study details as provided by Office of Rare Diseases (ORD):

Study Start Date:	March 1999
Study Completion Date:	March 2006
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Detailed Description:

PROTOCOL OUTLINE:

Patients receive escalating doses of droxidopa or placebo for 7-14 days. Patients undergo blood pressure measurements hourly in both supine and standing positions.

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Orthostatic hypotension due to autonomic nervous system failure Fall in systolic blood pressure (supine to standing) of at least 20 mm Hg and diastolic blood pressure of at least 15 mm Hg AND Symptoms of hypotension such as dizziness, light-headedness, unsteadiness, dimming or blurred vision
History of syncope or near-syncope

--Prior/Concurrent Therapy--

Endocrine therapy: No concurrent adrenergics Concurrent fludrocortisone allowed
Other: Concurrent indomethacin, support garments, and high salt diets allowed

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004478

Locations


United States, New York
	New York University School of Medicine
	New York, New York, United States, 10016

Sponsors and Collaborators

Mount Sinai School of Medicine

Investigators


Study Chair:	Horacio Kaufmann, MD	New York University School of Medicine

More Information

Publications of Results:

Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003 Aug 12;108(6):724-8. Epub 2003 Jul 28.

Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004 Dec;14(6):363-8.

Study ID Numbers:	199/14180, MTS-GCO-98-243-3-NE
First Received:	October 18, 1999
Last Updated:	September 17, 2008
ClinicalTrials.gov Identifier:	NCT00004478
Health Authority:	Unspecified

Keywords provided by Office of Rare Diseases (ORD):

Shy-Drager Syndrome

cardiovascular and respiratory diseases

neurologic and psychiatric disorders

orthostatic hypotension

rare disease

Study placed in the following topic categories:

Multiple system atrophy

Hypotension

Shy-Drager Syndrome

Multiple system atrophy (MSA) with orthostatic hypotension

Hypotension, Orthostatic

Ganglion Cysts

Respiration Disorders

Basal Ganglia Diseases

Rare Diseases

Vascular Diseases

Central Nervous System Diseases

Neurodegenerative Diseases

Brain Diseases

Postural hypotension

Autonomic Nervous System Diseases

Multiple System Atrophy

Movement Disorders

Mental Disorders

Droxidopa

Atrophy

Additional relevant MeSH terms:

Pathologic Processes

Disease

Anti-Dyskinesia Agents

Therapeutic Uses

Syndrome

Nervous System Diseases

Antiparkinson Agents

Cardiovascular Diseases

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	Mount Sinai School of Medicine
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004478